Type 1 Diabetes Mellitus
Conditions
Brief summary
This is an open-label, non-randomised pilot study, to evaluate user performance and system accuracy in blood Glucose monitoring system with glucose adjustment. Twelve male and female volunteers aged 18-45, with a documented diagnosis of Type I diabetes for at least 12 will be enrolled in this study.
Interventions
DEVICEBlood Glucose Monitoring Systems.
In vitro diagnostic medical device.
Sponsors
LifeScan
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
No
Inclusion criteria
Summary of inclusion criteria. * Male and female volunteers aged 18-45, with a documented diagnosis of Type I diabetes for at least 12 months and treated with a basal bolus insulin regime, and deemed otherwise healthy as determined by medical history, physical examination, laboratory test values, vital signs and 12-lead ECGs at screening. * Non-smokers from at least 12 months before study start and for the duration of the study. * Body mass index (BMI) ≥ 18 and ≤ 30 kg/m2. * Able to voluntarily provide written informed consent to participate in the study. * Must understand the purposes and risks of the study and agree to follow the restrictions and schedule of procedures as defined in the protocol, as confirmed during the informed consent process. * Must be willing to consent to have data entered into The Over Volunteering Prevention System (TOPS). * The volunteer's primary care physician has confirmed within the last 12 months that there is nothing in their medical history that would preclude their enrolment into a clinical study. * User Performance Accuracy Testing Only: Self-Monitoring - Volunteer is currently performing unassisted self-monitoring of blood glucose. Summary of
Exclusion criteria
. * A severe hypoglycaemic reaction, defined as causing loss of consciousness and/or requiring outside assistance with oral or intravenous glucose or a glucagon injection, within 7 days of the study start date. * Female volunteers who are pregnant or lactating. * Positive for human immunodeficiency virus (HIV), hepatitis B or hepatitis C. * Current or history of drug or alcohol abuse or a positive drugs of abuse or alcohol test at screening or check-in. * Participation in a clinical drug study during the 90 days prior to study start. * Any clinically significant illness within 30 days prior to study start. * Donation of blood or blood products within 30 days prior to study start, or at any time during the study, except as required by this protocol. * Weekly alcohol intake exceeding the equivalent of 14 units per week for females or 21 units per week for males. * Consumption of alcoholic beverages within 48 hours prior to check-in. * Volunteers with a substantial change in eating habits within 30 days prior to study start or volunteers who cannot comply with the standardised meals proposed for use in the study. * Prior experience with the BGMSs used for the study. * Volunteers who are currently working for, have previously worked for, or have an immediate family member working for a company that manufactures or markets blood glucose monitoring products. * Volunteers who have laboratory training or experience (medical technologist, laboratory technician, laboratory assistant etc). * Volunteers who, in the opinion of the Investigator, are unsuitable for participation in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| User Performance (UP) evaluation. | Up to 6 hours | UP evaluation of blood glucose monitoring systems compared to a reference instrument. Samples collected by subject and HCP |
| System Accuracy (SA) evaluation | Up to 6 hours | UP evaluation of blood glucose monitoring systems compared to a reference instrument. Samples collected by HCP only. |
Countries
United Kingdom
Outcome results
None listed